|

RP-3500 Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Camonsertib

Other1 trial

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Phase 2

Los Angeles, California1 trial

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

# 1019, UCLA, Westwood Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.